Cargando…

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study

The aim of this phase I study is to evaluate, for the first time, the safety and efficacy of sintilimab in pediatric patients diagnosed with advanced or recurrent malignancies. During the dose escalation phase, patients received a single intravenous infusion of sintilimab at varying doses of 1, 3, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Que, Yi, Wang, Juan, Sun, Feifei, Wang, Shan, Zhu, Jia, Huang, Junting, Zhao, Zhenzhen, Zhang, Li, Liu, Juan, Xu, Jiaqian, Zhen, Zijun, Sun, Xiaofei, Lu, Suying, Zhang, Yizhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570390/ https://www.ncbi.nlm.nih.gov/pubmed/37828033 http://dx.doi.org/10.1038/s41392-023-01636-9

Ejemplares similares

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China
por: Hong, Ye, et al.
Publicado: (2023)

Long‐term follow‐up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities
por: Zeng, Chenggong, et al.
Publicado: (2023)

Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children
por: Zhu, Jia, et al.
Publicado: (2021)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study
por: Lan, Yingxia, et al.
Publicado: (2023)

Identification of prognostic immune-related genes in rhabdoid tumor of kidney based on TARGET database analysis
por: Chen, Huimou, et al.
Publicado: (2021)

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen
por: Zhu, Xiaoqin, et al.
Publicado: (2021)

Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients
por: Lu, Suying, et al.
Publicado: (2021)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Multimodal Treatment of Children With Sacrococcygeal Yolk Sac Tumor: Retrospective Analysis of Clinicopathology Characteristics and Relapse-free Survival
por: Zhu, Jia, et al.
Publicado: (2021)

Role of post-chemotherapy radiation in the management of children and adolescents with primary advanced malignant mediastinal germ cell tumors
por: Huang, Junting, et al.
Publicado: (2017)

Investigation of chemoresistance to first-line chemotherapy and its possible association with autophagy in high-risk neuroblastoma
por: Chen, Tingting, et al.
Publicado: (2022)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China
por: Huang, Junting, et al.
Publicado: (2020)

KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis
por: Chen, Binbin, et al.
Publicado: (2022)

Bioinformatics Analysis and Validation Identify CDK1 and MAD2L1 as Prognostic Markers of Rhabdomyosarcoma
por: Lu, Suying, et al.
Publicado: (2020)

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era
por: Sun, Feifei, et al.
Publicado: (2018)

Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies
por: Sun, Xiaofei, et al.
Publicado: (2021)

ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma
por: Li, Mengzhen, et al.
Publicado: (2021)

Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients
por: Lan, Yingxia, et al.
Publicado: (2023)

Long-Term Outcomes of Nasopharyngeal Carcinoma in 148 Children and Adolescents
por: Lu, Suying, et al.
Publicado: (2016)

A multicenter phase II trial of primary prophylactic PEG‐rhG‐CSF in pediatric patients with solid tumors and non‐Hodgkin lymphoma after chemotherapy: An interim analysis
por: Huang, Junting, et al.
Publicado: (2023)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Que, Yi, et al.
Publicado: (2021)

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma
por: Sun, Chengtao, et al.
Publicado: (2020)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma
por: Sun, Chengtao, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
por: Zhang, Shuang, et al.
Publicado: (2018)

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors
por: Huang, Nana, et al.
Publicado: (2022)

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial
por: Xu, Qin, et al.
Publicado: (2022)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial
por: Guo, Chengxiang, et al.
Publicado: (2023)

A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma
por: Zheng, Siming, et al.
Publicado: (2023)

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
por: Tian, Zhichao, et al.
Publicado: (2022)

Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report
por: Zhang, Lin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5aglktc1ofimtbknbk1e8hp2go